<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink">
    <mets:dmdSec ID="DMD_ef5a6cbe-2f09-4d84-87d8-c8aaef308a36">
        <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
            <mets:xmlData>
                <mods xmlns="http://www.loc.gov/mods/v3" version="3.7" xmlns:vl="http://visuallibrary.net/vl">
                    <titleInfo lang="eng">
                        <title>Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways</title>
                    </titleInfo>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1015600905">
                        <displayForm>Ibrahim, Sherif</displayForm>
                        <namePart type="given">Sherif</namePart>
                        <namePart type="family">Ibrahim</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1128879050">
                        <displayForm>Gadalla, Ramy</displayForm>
                        <namePart type="given">Ramy</namePart>
                        <namePart type="family">Gadalla</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/110948965X">
                        <displayForm>El-Ghonaimy, Eslam A.</displayForm>
                        <namePart type="given">Eslam A.</namePart>
                        <namePart type="family">El-Ghonaimy</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1128879069">
                        <displayForm>Samir, Omnia</displayForm>
                        <namePart type="given">Omnia</namePart>
                        <namePart type="family">Samir</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1122722427">
                        <displayForm>Mohamed, Hossam Taha</displayForm>
                        <namePart type="given">Hossam Taha</namePart>
                        <namePart type="family">Mohamed</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1030128227">
                        <displayForm>Hassan, Hebatallah</displayForm>
                        <namePart type="given">Hebatallah</namePart>
                        <namePart type="family">Hassan</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1030128227">
                        <displayForm>Eshmawy, Hebatallah</displayForm>
                        <namePart type="given">Hebatallah</namePart>
                        <namePart type="family">Eshmawy</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal">
                        <displayForm>Greve, Burkhard</displayForm>
                        <namePart type="given">Burkhard</namePart>
                        <namePart type="family">Greve</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1096682397">
                        <displayForm>El-Shinawi, Mohamed</displayForm>
                        <namePart type="given">Mohamed</namePart>
                        <namePart type="family">El-Shinawi</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1109489668">
                        <displayForm>Mohamed, Mona Mostafa</displayForm>
                        <namePart type="given">Mona Mostafa</namePart>
                        <namePart type="family">Mohamed</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/120035715">
                        <displayForm>Götte, Martin</displayForm>
                        <namePart type="given">Martin</namePart>
                        <namePart type="family">Götte</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <typeOfResource>text</typeOfResource>
                    <genre authority="dini">article</genre>
                    <originInfo>
                        <dateIssued encoding="w3cdtf" keyDate="yes">2017-03-07</dateIssued>
                        <dateIssued encoding="w3cdtf">2018-04-11</dateIssued>
                    </originInfo>
                    <language>
                        <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
                    </language>
                    <abstract lang="eng">BACKGROUND: Inflammatory breast cancer (IBC), a particularly aggressive form of breast cancer, is characterized by cancer stem cell (CSC) phenotype. Due to a lack of targeted therapies, the identification of molecular markers of IBC is of major importance. The heparan sulfate proteoglycan Syndecan-1 acts as a coreceptor for growth factors and chemokines, modulating inflammation, tumor progression, and cancer stemness, thus it may emerge as a molecular marker for IBC. METHODS: We characterized expression of Syndecan-1 and the CSC marker CD44, Notch-1 &amp; -3 and EGFR in carcinoma tissues of triple negative IBC (n = 13) and non-IBC (n = 17) patients using qPCR and immunohistochemistry. Impact of siRNA-mediated Syndecan-1 knockdown on the CSC phenotype of the human triple negative IBC cell line SUM-149 and HER-2-overexpressing non-IBC SKBR3 cells employing qPCR, flow cytometry, Western blotting, secretome profiling and Notch pharmacological inhibition experiments. Data were statistically analyzed using Student’s t-test/Mann-Whitney U-test or one-way ANOVA followed by Tukey’s multiple comparison tests. RESULTS: Our data indicate upregulation and a significant positive correlation of Syndecan-1 with CD44 protein, and Notch-1 &amp; -3 and EGFR mRNA in IBC vs non-IBC. ALDH1 activity and the CD44(+)CD24(-/low) subset as readout of a CSC phenotype were reduced upon Syndecan-1 knockdown. Functionally, Syndecan-1 silencing significantly reduced 3D spheroid and colony formation. Intriguingly, qPCR results indicate downregulation of the IL-6, IL-8, CCL20, gp130 and EGFR mRNA upon Syndecan-1 suppression in both cell lines. Moreover, Syndecan-1 silencing significantly downregulated Notch-1, -3, -4 and Hey-1 in SUM-149 cells, and downregulated only Notch-3 and Gli-1 mRNA in SKBR3 cells. Secretome profiling unveiled reduced IL-6, IL-8, GRO-alpha and GRO a/b/g cytokines in conditioned media of Syndecan-1 knockdown SUM-149 cells compared to controls. The constitutively activated STAT3 and NFκB, and expression of gp130, Notch-1 &amp; -2, and EGFR proteins were suppressed upon Syndecan-1 ablation. Mechanistically, gamma-secretase inhibition experiments suggested that Syndecan-1 may regulate the expression of IL-6, IL-8, gp130, Hey-1, EGFR and p-Akt via Notch signaling. CONCLUSIONS: Syndecan-1 acts as a novel tissue biomarker and a modulator of CSC phenotype of triple negative IBC via the IL-6/STAT3, Notch and EGFR signaling pathways, thus emerging as a promising therapeutic target for IBC.</abstract>
                    <note type="citation/reference">Molecular Cancer 16 (2017) 57, 1-19</note>
                    <note>Finanziert durch den Open-Access-Publikationsfonds 2017 der Westfälischen Wilhelms-Universität Münster (WWU Münster).</note>
                    <subject lang="eng">
                        <topic>Inflammatory breast cancer</topic>
                        <topic>Syndecan-1</topic>
                        <topic>Proteoglycan</topic>
                        <topic>Cancer stem cell</topic>
                        <topic>IL-6/STAT3</topic>
                        <topic>Notch</topic>
                        <topic>EGFR</topic>
                    </subject>
                    <classification authority="ddc">610</classification>
                    <identifier type="urn">urn:nbn:de:hbz:6-98199544976</identifier>
                    <identifier type="doi">10.1186/s12943-017-0621-z</identifier>
                    <accessCondition type="use and reproduction" xlink:href="http://creativecommons.org/licenses/by/4.0/">CC BY 4.0</accessCondition>
                    <recordInfo>
                        <recordIdentifier>muenster_miami_ef5a6cbe-2f09-4d84-87d8-c8aaef308a36</recordIdentifier>
                    </recordInfo>
                    <extension>
                        <vl:doctype>oaArticle</vl:doctype>
                    </extension>
                </mods>
            </mets:xmlData>
        </mets:mdWrap>
    </mets:dmdSec>
    <mets:fileSec>
        <mets:fileGrp USE="pdf upload">
            <mets:file MIMETYPE="application/pdf" ID="FILE_ef5a6cbe-2f09-4d84-87d8-c8aaef308a36_1">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/ef5a6cbe-2f09-4d84-87d8-c8aaef308a36/2017_artikel_goette.pdf" LOCTYPE="URL"/>
            </mets:file>
        </mets:fileGrp>
    </mets:fileSec>
    <mets:structMap TYPE="LOGICAL">
        <mets:div TYPE="document" ID="muenster_miami_ef5a6cbe-2f09-4d84-87d8-c8aaef308a36" DMDID="DMD_ef5a6cbe-2f09-4d84-87d8-c8aaef308a36">
            <mets:fptr FILEID="FILE_ef5a6cbe-2f09-4d84-87d8-c8aaef308a36_1"/>
        </mets:div>
    </mets:structMap>
</mets:mets>
